Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANT-1207 + botulinum toxin type A
- Development stage
- Discontinued
- Lead developer
- Allergan
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
ANT-1207 + botulinum toxin type A is a **topical formulation** that combines the proprietary compound ANT-1207 with purified **botulinum toxin type A**. Developed for local dermatological disorders, this drug acts by inhibiting acetylcholine release at neuromuscular junctions and possibly also antagonizing glutamate signaling, thereby blocking sweat gland activity and muscle contraction when applied topically. Its primary clinical development focused on **acne vulgaris**, **facial wrinkles**, and **hyperhidrosis** (excessive sweating)[1][2][4][8]. The mechanism of action includes **acetylcholine inhibition** and **neuromuscular blockade**, leading to local reduction in muscle activity and sweat production. The developer was initially Anterios, with subsequent development by Allergan (now AbbVie)[1][2][6].
- Other names
- botulinum toxin A topicalbotulinum toxin type A topical liniment
02
Targets
SV2A (Synaptic vesicle glycoprotein 2A)SNAP25 (Synaptosome-associated protein 25)
Beyond the preview
Go deeper on ANT-1207 + botulinum toxin type A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANT-1207 + botulinum toxin type A.